-       Report 
   - November 2025
    -  235 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - November 2025
    -  374 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - November 2025
    -  419 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - November 2025
    -  578 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - November 2025
    -  577 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                 -       Report 
   - November 2025
    -  380 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - November 2025
    -  172 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - November 2025
    -  488 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - November 2025
    -  372 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - November 2025
    -  184 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - November 2025
    -  382 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - November 2025
    -  360 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - November 2025
    -  181 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - November 2025
    -  182 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - November 2025
    -  262 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - November 2025
    -  213 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - November 2025
    -  196 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - November 2025
    -  293 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - November 2025
    -  294 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - September 2025
    -  185 Pages 
    Global
   
   From       €4038EUR$4,500USD£3,544GBP 
             
         The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are    typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less   Read more